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Abstract
Although originally considered merely structural components of cellular membranes, glycosphingolipids (GSL) are
now recognized as having critical effects on cellular physiology, including proliferation, differentiation, viral
transformation and ontogenesis. In addition, a vast majority of human cancers have modified GSL composition
compared to parental normal cells. These modifications may contribute to both tumor survival and exert striking
effects on anti-tumor immunity. In this review, we discuss mechanisms of immune modulation by tumor-secreted
GSL.
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Introduction
Since their first isolation from human brain by JLW Thudichum in
the late 1800’s, glycosphingolipids (GSL; lipid-rich molecules, widely
expressed in normal tissues) were considered mere structural
components of cell membranes. Over time, numerous reports have
described changes in GSL composition and levels associated with cell
proliferation, differentiation, viral transformation and ontogenesis [1].
A vast majority of human cancers exhibit striking differences in
GSL composition when compared to parental normal cells (reviewed
in [2]). These modifications may contribute to both tumor survival
and exert striking effects on anti-tumor immunity. In this review, we
describe mechanisms of GSL-mediated immune-modulation.
Glycosphingolipids: structure and function in
homeostasis
Glycosphingolipids (GSL) are a group of complex lipids that exhibit
amphipathic features, allowing their insertion into cellular bilayers.
Their amphipathic nature derives from the presence of a lipid region
(consisting on N-acylsphingosine, or ceramide) covalently linked to a
glycosidic region [3], as exemplified in Figure 1a. Ceramide may
contain variations in either the sphingosine or the fatty acid (such as
chain length, hydroxylation and/or saturation degree). Regarding the
glycosidic region, it can vary in number and sequence of glycans,
which in addition can have variability in their glucidic position and
anomeric configuration. This structural versatility might explain the
existence of more than 200 different GSL known up to date, which
have been purified from a wide diversity of eukaryotic organisms [4].
This variability is relevant because, just as the primary sequence of
proteins influences their secondary and tertiary structures, the specific
oligosaccharides present in GSL, glycoproteins and other
glycoconjugates affect the molecules’ three-dimensional conformation
[5].
Figure 1: Structural features and variability of GSL. A, GM1 as an
example of a GSL structure. The different components accounting
for the amphipathic behavior of GSL (carbohydrate and ceramide
moieties) are exhibited, along with its equivalent schematic
representation in accordance to the “Consortium for Functional
Glycomics” recommendations. B, Names and structure sequences
for the main mammal GSL series having altered expression in
tumors.
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GSL are classified based on the closest neutral glycosidic sequences
bound to the ceramide domain. Each group of GSL being metabolic
intermediates along the different biosynthetic pathways that
sequentially add carbohydrates to ceramide is known as a “series”.
These neutral core structures can further elongate by adding a variable
number of molecules, including N-acetyl neuraminic acid (sialic acid)
residues. The major GSL correlating with specific tumors belong
mostly to four series: lacto-, neolacto-, globo- and ganglio-series.
Figure 1b exhibits the core sequences for these four main series.
GSL make up a significant portion of most eukaryotic cell
membranes, adopting unique patterns for each cell type. Molar ratios
of these molecules related to other major membrane lipids (such as
phospholipids, cholesterol and glycerolipids) range from very low (i.e.,
<5% in erythrocytes) to relatively high (i.e., >30% of total lipids on
oligodendrocytes plasma membrane, [6]). Surface-labeling
experiments indicate GSL are inserted in the external layer of the cell
through ceramide, and by their presence in the membrane regulate cell
signaling. This is accomplished by altering the distribution of
receptors in the cell membrane and by directly interacting or forming
lipid domains that have preferential affinity for certain proteins, thus
modifying their function [7]. GSL may also modulate cellular
physiology by specifically binding other GSL or adjacent cell proteins
to influence cell-cell or cell-environment interactions that regulate
differentiation, cell growth and tissue organization [8-15].
Regulatory mechanisms of glycosphingolipid synthesis
and their disruption in tumor cells
General mechanisms of GSL synthesis. GSL are not direct products
of genes. Instead, they are synthesized through a complex series of
coordinated biosynthetic pathways comprised of several integral
membrane glycosyltransferases. Eukaryotic GSL synthesis begins in
the endoplasmic reticulum (ER) with the formation of the lipophilic
ceramide tail. The β-addition of either a galactose (on the luminal face
of the ER) or a glucose residue (on the cytoplasmic face of the ER and
early Golgi complex) to the 1-hydroxyl of ceramide generates GalCer
or GlcCer, respectively. Once at the Golgi complex, GalCer can be
sulfated to produce acidic GSL (Sulfatide). Incorporation of galactose
to GlcCer yields lactosylceramide (LacCer), a common precursor for
the base structures of the different GSL series described in Figure 1.
Most LacCer are further elongated at the Golgi lumen by a series of
glycosyltransferases that define the composition of GSL in a cell by
their expression and intracellular distribution. These enzymes are
regulated at the transcriptional, translational or post-translational level
[16-18]. Additional regulation occurs through the availability of the
sugar nucleotides and precursor acceptors as different enzymes may
compete for the same substrate. Furthermore, different GSL
glycosyltransferases may associate to form functional
“multiglycosyltransferase” complexes that ensure progression to the
preferred end product without releasing intermediate structures [19].
Changes in GSL synthesis in tumors. Aberrant GSL glycosylation
occurs frequently in tumors (see Figure 2 [2]). The changes may be
due to incomplete synthesis of certain GSL with the accumulation of
precursors [20]. Early branch point alterations in the normal
biosynthetic pathway can thus affect the amount of one class of GSL
structure and allow the dominance of another to emerge. Epigenetic
changes diminish expression of specific transferases (e.g. B4GalNAcT2,
ST3Gal6, ST6GalNAc6 and GlcNAc6ST) in gastrointestinal tumors,
altering the enzymatic activity of the concert of transferases and thus
causing the accumulation of sialyl Lewisx and sialyl Lewisa [21,22]. In
addition, hypoxic conditions can increase the expression of HIF
(hypoxia inducible factor), which induces the transcription of
glycosyltransferases FUT7 and ST3Gal-1 and transporter UGT1, also
leading to sialyl Lewisx and sialyl Lewisa formation [23]. In adult T-
cell leukemia, caused by Human T-cell Leukemia Virus type 1
(HTLV-1), the transcription of the FUT7 is constitutively activated by
Tax protein (a viral molecule), increasing sialyl Lewisx synthesis [24].
Figure 2: GSL molecules with altered expression in different types
of cancer. Series, name and structure are listed for each GSL, along
with the tumor type they are found to be altered.
Enhanced “neosynthesis” of GSL, which are minimal or absent in
normal cells or tissues also leads to aberrant GSL in tumors [20].
Abnormal sialylation is a frequent alteration on tumor cells. For
example, malignant melanomas have 9-O-acetylated GD3 instead of
GD3 found in normal cells [25] and a critical ratio between GD3 and 9-
O-acetyl GD3 on glioblastoma promotes tumor survival [26]. In fact,
restoring GD3 by acetyl group cleavage reduces tumor cell viability by
induction of mitochondrial-mediated apoptosis.
Another example of abnormal sialylation is represented by the loss
of an acetyl group of GM3 (de-N-acetyl GM3) [27], leading to
enhanced EGF-dependent tyrosine kinase activity of the epidermal
growth factor (EGF) receptor while GM3 in normal cells inhibits EGF-
stimulated tyrosine phosphorylation of the EGF receptor [28]. In
addition, de-N-acetyl GM3 increases the expression and activation of
urokinase-like plasminogen activator (uPA) and activates matrix
metalloproteinase-2 in metastatic melanoma, thus stimulating cell
migration and invasion [29].
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Aberrant GSL glycosylation in tumors may also occur due to the
increased use of recycling pathways. Although humans lack the
enzyme to convert N-acetylneuraminic acid (Neu5Ac) to N-
glycolylneuraminic acid [30], dietary uptake provides Neu5Gc through
lysosomal sialidase activity on endocytosed Neu5Gc-bearing
glycoconjugates. This free Neu5Gc is then transported into the cytosol,
reactivated with cytidine triphosphate (CTP) in the nucleus [31], and
preferentially utilized by tumors [32]. Thus, the usual Neu5Ac
molecule is replaced by Neu5Gc, leading to the aberrant expression of
Neu5Gc in tumors. This molecule, which differs from Neu5Ac by a
single oxygen atom, has been shown to sustain low-grade chronic
inflammation that can facilitate tumor progression through growth-
promoting and angiogenic signals [33].
GSL shedding and uptake
Increased levels of aberrant GSL are present in patients with various
tumors. The idea that tumors might shed GSL into the extracellular
space dates back to an observation nearly 40 years ago in breast cancer
patients who had elevated serum levels of sialic acid-containing GSL
[71]. Portoukalian et al. later found that the same GSL shed by
melanomas were also enriched in erythrocyte plasma membranes of
melanoma patients [72]. These associative findings suggested a clinical
relevance for dysregulated GSL synthesis and shedding. In fact,
increased levels of circulating GD2 in patients with neuroblastoma at
the time of diagnosis were correlated with faster disease progression
and lower survival rate [73]. In addition, GD3 levels in sera from
patients with different stages of astrocytomas and glioblastomas were
proportionally higher with more aggressive World Health
Organization histologic grade [66]. Similarly, serum fucosyl-GM1
levels in small cell lung carcinoma patients positively correlated with
the presence of multiple site metastases [70]. Lastly, serum levels of
total gangliosides correlated with clinical course in melanoma patients
after immunotherapy with a therapeutic cancer vaccine [74].
Figure 3 summarizes the process of shedding and uptake. The
physiologic significance of GSL shedding and uptake is unknown. By
transferring molecules, GSL shedding provides a mechanism to alter
diverse surface properties on donor and/or acceptor cells [75-79]. In
tumors, GSL shedding occurs rapidly (≈0.1 to 0.5% of total cell GSL
per hour [59,67]). Although the concentration of GSL in the
extracellular milieu depends on the GSL pattern of the tumor (as seen
for human malignant melanomas [80]), shorter lengths of the
ceramide fatty acyl chain may determine the preferential shedding of
various GSL by different tumor cells [81,82] and also may influence
their immunosuppressive activity.
In neuroblastoma patients, circulating GD2 is largely bound to
serum lipoproteins, approximately 75% binding LDL [83]. Dual
chamber culture experiments have documented cell to cell transfer of
GSL shed from lymphoma [84] and medulloblastoma [85] cell lines to
human fibroblasts. Interestingly, inhibitors of GSL synthesis diminish
the shedding and transfer of potentially biologically active GSL from
the tumor [85], and also reduced the ability of murine melanomas to
form tumors [86].
Studies on ovarian carcinoma cell lines suggest GSL-containing
membrane vesicle shedding originates in plasma membrane domains
enriched in GSL and caveolin-1 [87]. However, the shed GSL can be
found in different forms that include not only large complexes
(membrane vesicles), but also micelles and monomers [88]. Analyses
on the relative composition of GSL suggest they could also be shed
from cell membranes via a mechanism of preferential release for some
particular GSL components [82].
Figure 3: Different mechanisms of GSL shedding by tumor cells and
uptake by neighboring cells. A considerable fraction of the GSL
produced by a tumor cell (donor) in high concentration is released
to the extracellular milieu, where is found in the form of monomers
(1), micelles (2), or as part of larger complexes, such as lipoprotein
particles (3) and membrane vesicles (4), GSL can potentially
transfer between each of these forms, and to the plasma membrane
of other cells (acceptor).
Immunomodulatory mechanisms of GSL
The advent of immunotherapies for cancer has resulted in durable
clinical responses and confirmed that immune responses may prevent
cancer progression [89]. Moreover, tumor-infiltrating immune cells
correlate with a positive outcome in many types of cancer [90-93].
However, chronic inflammation is associated with cancer, and certain
immune cells (e.g., T regulatory cells) are associated with disease
progression [94]. To resolve this paradoxical relationship between
cancer and the immune system, a current paradigm is referred to as
immune editing [95]. Immune elimination of tumor cells selects for
tumor cells that are poorly recognized, which may ultimately escape
immune recognition when the tumor creates an immunosuppressive
environment. Tumors may shed different GSL to create conditions for
evading immune surveillance, leading to a favorable environment for
tumor progression. The GSL shed by the tumor may alter the
membrane composition of infiltrating immune cells and inhibit their
function, allowing tumor escape.
Monocytes, macrophages, and dendritic cells (DC). Cells of the
innate immune system, including monocytes, macrophages, and
dendritic cells, control tumors by killing tumor cells directly, secreting
inflammatory mediators that recruit and differentiate adaptive
immune cells, and presenting tumor antigens to T cells [96-98].
However, the latter two (indirect) antitumor functions of innate
immune cells are inhibited by GSL in general, and particularly by
those altered GSL found on tumor cells (see Figure 4, parts “1” and
“2”).
Monocyte/macrophages. Monocytes exposed to bovine brain
gangliosides [99], human brain gangliosides [100], or purified GD1a
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[101] fail to stimulate antigen-specific lymphoproliferative responses.
Gangliosides prevent up-regulation of the co-stimulatory molecule
CD80, whereas expression of ICAM-1, LFA-3, HLA-DR, and CD86 is
not affected. Accordingly, monocytes pre-incubated with GD1a also
show inhibition of CD80 up-regulation, down-regulation of CD40 and
reduced IL-12 and TNF-α release in response to LPS stimulation [101],
events that could be mediated by impeding NF-κB mobilization [102].
Moreover, previous exposure of monocytes to GM2 and GM3, or to
GM1 and GD3, exhibit reduced Fc receptor expression and IL-1
production, respectively [103]. GM3, in particular, inhibits the VEGF-
induced in vivo and in vitro expression of adhesion molecules
(ICAM-1 and VCAM-1) on endothelium (in a mechanism mediated
by activation of NF-κB via AKT signaling), and reduces monocyte
adhesion to endothelial cells [104]. All these events lead to impaired
leukocyte recruitment to endothelial cells under inflammatory stimuli,
ultimately resulting detrimental to an effective anti-tumor immune
response.
Dendritic cells. Development and function of monocyte-derived
DC can be affected by gangliosides including GM2 [105], GD1a [106],
GM3 and GD3 [107] in vitro, suggesting GSL may influence DC
differentiation in vivo. The presence of GM2 changes the morphology,
adherence, and cell surface receptor expression of DC precursors. For
example, MHC class II molecules, costimulatory molecules and CD116
(GM-CSF receptor) are significantly reduced, as well as their
endocytic, chemotactic and T cell proliferation-inducing activities. DC
preincubated with GD1a poorly up-regulate costimulatory molecules
and exhibit reduced IL-12 and increased IL-10 production when
exposed to antigenic bacterial toxins [106]. Meanwhile, GM3 and GD3
strongly down-regulate CD1a, CD54, CD80 and CD40 molecules, impair
allostimulatory functions, reduce IL-12 and increase IL-10 production,
and induce caspase 3-mediated apoptosis [107]. The mechanisms by
which GM3 and GD3 induce apoptosis differ in that GM3 causes
accumulation of sphingomyelinase-generated ceramides and GD3-
induced apoptosis is dependent on reactive oxygen species [108].
Although mature DC appear to be resistant to the GM2-mediated
inhibitory effect, GD1a-preincubated DC exhibit no CD80 up-
regulation, and also downregulate CD40, IL-12, TNF-α and IL-6 in
response to LPS [101]. These activated DC show evidence of NF-κB
activation disruption, which may account for ganglioside interference
with APC expression of costimulatory molecules and cytokine
secretion. In summary, GSL dysregulation in tumors acts to prevent T
cell recognition by interfering with various macrophage and DC
functions.
B cells. B cells in the tumor environment may produce antitumor
antibodies that target tumor for killing by effector cells, as well as
present antigens to T cells. In vitro studies show that GM2 ganglioside
inhibits spontaneous immunoglobulin production on isolated B cells,
by inhibiting endogenous IL-10 and TNF-α production [109]. GD1b or
GT1b also can affect B cells by inhibiting spontaneous IgG, IgM and
IgA production; however the effect is indirect in that treatment of T
cells or isolated monocytes with GD1b or GT1b alters T cells and
monocytes. GD1b caused decreased IL-6 and IL-10 production from
CD4 T cells [110]. GT1b has a similar effect on monocytes [111]. When
these ganglioside-treated T cells or monocytes are then co-cultured
with B cells, antibody production is decreased. In contrast, GQ1b [112]
and GD1a [113] can counteract the effects of GD1b and GT1b,
respectively, and thus enhance Ig production by human PBMC.
Meanwhile, GM2 and also GM3 gangliosides inhibit B cell production
of IgG subclasses and IgM, with no effect on IgA subclasses [114].
Addition of TNF-α can counteract these inhibitions. Taken together,
these studies show that GSL can negatively impact antitumor Ig
production (see Figure 4, part “3”), but their effect on B cell antigen
presentation has not been determined.
Figure 4: GSL modulate anti-tumor activity of immune cells.
Different immune cells act concertedly on promoting tumor cell
death through multiple mechanisms. Many of these mechanisms
are influenced negatively by GSL shed from tumor cells. For
example, GSL can affect the expression of costimulatory molecules
and proinflammatory cytokine release from macrophages (1). In
addition, GSL interferes with dendritic cell capabilities to promote
antigen-specific T cell activation (2). The spontaneous antibody
production on B cells (3) is also inhibited by GSL. Type 1 T cell
responses driven by CD4 T cells (4), including antigen-specific
activation, production of IFN-γ and IL-2-mediated T cell expansion
are impaired, whereas type 2 responses are favored or not affected
to the same extent. GSL affect negatively the formation and also the
granule exocytosis-mediated cytotoxicity of antigen-specific CD8+
cytotoxic T cells (5). Various GSL have also been shown to prevent
NKT cell activation (6). Green arrows represent actions performed
by immune cells, whereas red lines indicate effects mediated by
shed GSL. See main text for details.
CD4 T cells, CD8 cytotoxic T cells, NKT cells. T cells play an
important role in anti-tumor immunity, as helper cells for antibody
production and cell-mediated immune responses as well as effector
cells for tumor killing [115].
CD4 helper T cells. Type-1 T cell responses (represented by IFN-γ-
and IL-2-producing T cells) are essential for the induction of cytolytic,
anti-tumor immunity [116] while type-2 T cells producing IL-4, IL-6
and IL-10 are related to suppression of cytolytic activity [117]. In fact,
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cancer patients show increased type-2 cytokine production [118]. GSL
influence T cell activation at numerous levels, including transcription
of T helper cytokine genes, ligand-receptor binding of cytokines,
antigen presentation, and T cell apoptosis (see Figure 4, part “4”).
Rel/NF-кB regulate transcription of a large number of genes involved
in T-cell development, maturation and proliferation [119].
Gangliosides derived from renal cell carcinomas (RCC) inhibit NF-кB
activity in T cells, reduce IL-2 and IFN-γ expression [120] and increase
apoptosis [121]. These changes are mediated by a decrease in the levels
of RelA(p65), p50 and the antiapoptotic protein Bcl-xL (in a caspase
dependent pathway), and can be impeded by blocking ganglioside
synthesis [121].
When present during anti-CD3 antibody-induced activation of
murine T cells, GT1b ganglioside reduces the levels of IFN-γ and
increases IL-4, compatible with a shift towards a type-2 response [122].
Whereas the IFN-к reduction occurs in both CD4+ and CD8+ cell
populations, the IL-4 enhancement is observed only in CD4+ T cells.
However, the effects on the production of these two cytokines appear
to be independent of each other. Similarly, human T cells activated in
the presence of (RCC)- or brain-derived gangliosides show inhibition
of IFN-γ (mRNA and protein) responses, apoptosis of activated T
cells, but no influence on type-2 cytokines IL-4, IL-5 and IL-10
[123,124]. These findings are correlated in vivo, where T cells from
RCC patients display a greater level of apoptosis. Interestingly, most of
the apoptotic cells are GM2+ (GD2+ or GD3+) T cell populations, even
though the mRNA expression levels for GM2 synthase are negligible
[125]. Therefore, it is tempting to speculate that the ectopic presence
of GM2 on apoptotic T cells is derived from the tumor, and that GM2
may be involved in triggering apoptosis. GSL-induced apoptosis is
mediated by various mechanisms including reactive oxygen species,
reduction of NF-кB-dependent antiapoptotic protein expression levels,
induction of cytochrome c release and activation of caspases 3, 8 and 9,
occurring on activated but not resting T cells [125-127]. Although
opposed effects for some of these type-2-promoting changes are
observed using more complex gangliosides such as GD1b, GT1b and
GQ1b [128], this can be attributed to the usage of experimental
conditions involving phytohemagglutinin (PHA)-stimulation of T
cells. PHA engages multiple different glycosylated surface proteins,
leading to activation of several, confounding different signaling
pathways [129].
Antigen-specific activation of T cells requires the active
participation of antigen presenting cells (APC) such as DC,
macrophages and certain B cells, whose functions are affected by
certain GSL. Ganglioside pretreatment of DC reduces antigen
presentation to naïve T cells, leading to diminished proliferation and,
accordingly, fewer IFN-γ-producing cells (type-1) and IL-4-producing
cells (type-2) [106]. Among the molecular events implicated in
antigen-specific activation of T cells, binding of IL-2 to its cell surface
receptor (IL-2R) on T cells constitutes a critical step, in order to
proceed through the G1 checkpoint of the cell cycle and trigger DNA
synthesis and replication [130]. Brain-derived gangliosides can also
interfere with these events by blocking IL-2 gene transcription in
activated human T cells [124], and preventing phosphorylation of
retinoblastoma protein (RB, a regulator of cell cycle progression)
[124]. Moreover, mixtures of mono-, di- and tri-sialo gangliosides
inhibit IL-2-stimulated proliferation of IL-2-dependent cell lines,
CTLL-2 and HT-2 [131]. This dose-dependent effect occurs through
direct binding of a lectin-like site on IL-2 to gangliosides, thus creating
a competitive inhibition for IL-2 binding to IL-2R. A similar
mechanism of direct cytokine-ganglioside interaction is thought to
explain ganglioside-mediated inhibition of IL-4-stimulated helper T
cell proliferation [132].
CD8 cytotoxic T cells. Cytotoxic T cells (CTL) mediate antitumor
immunity by directly killing tumor cells [133]. The expansion of CTL
is affected by GSL exposure. When splenocytes from mice immunized
with FBL-3 erythroleukemia cells are rechallenged in vitro with
irradiated FBL-3 tumor in the presence of gangliosides shed by these
erythroleukemia cells, the tumor-specific response and the generation
of CTL are suppressed. These GSL can impair responses to a
secondary challenge as well (measured as reduced lymph node mass,
cell number and proliferation), when coinjected in vivo with a primary
FBL-3 cell immunization in mice [134]. An inhibition of the increase
of draining lymph node T cells (CD3+) is also observed [134]. In
addition, gangliosides can also influence the function of CTL (Figure
4, part “5”). Tumor-derived and individual highly purified
gangliosides inhibit granule exocytosis-mediated cytotoxicity of
alloantigen-specific and polyclonal CD8+ CTL [135]. Interestingly,
they have no influence on lytic molecule expression, nor do they
interfere with target cell recognition. Instead, they inhibit lytic granule
release from CD8+ CTL by preventing TCR-induced lytic granule
polarization, immunological synapse accumulation, and exocytosis
[135].
Natural Killer T cells. Another cell type for which antitumor activity
has been demonstrated is natural killer T (NKT) cells (Figure 4, part
“6”). These T cells recognize a variety of both exogenous and
endogenous lipid and glycolipid antigens presented in CD1 molecules,
cell surface glycoproteins structurally resembling to MHC I molecules
[136]. Upon activation, NKT cells produce cytokines that can
influence immune responses against tumors [137]. Although GD3 can
induce a GD3-reactive NKT cell response in melanoma [138], it is
found to prevent NKT cell activation in ovarian cancer [139]. GM3 can
also act as an inhibitory ligand for the NKT cell response to GD3 [140].
Asialo-GM2, shed from the murine T cell lymphoma line L5178Y-R, is
another glycosphingolipid that prevents NKT cell recognition [141].
Concluding Remarks
GSL are components of the external leaflet of plasma membranes
and, as such, participate in numerous events of cellular interaction.
Distinct GSL structures are generated through a series of intricate
biosynthetic processes in the Golgi that are fine-tuned by several
mechanisms. Tumors present several alterations in their GSL content.
Equally important, GSL are actively released from the membrane of
tumor cells and can bind immune cells to influence their function
through multiple mechanisms, having a strong impact on impairing
antitumor immunity and allowing tumor immune escape.
As auto-antigens present on normal cells at low levels, GSL are
poorly immunogenic. Over several years, different strategies aimed at
promoting anti-ganglioside immune responses have been studied, with
disparate success. Besides the direct vaccination with GSL conjugated
to adjuvants such as keyhole limpet haemocyanin [142], other
approaches like anti-idiotypic antibodies [143], chimeric T cells [144],
genetically-engineered antibodies [145] and GSL-mimicking peptides
[146] have been assayed. These various strategies have been
extensively reviewed elsewere [147,148].
Successful immune cell- or antibody-responses again GSL have the
ability not only to target and kill tumor cells, but also to reduce the
bioavailability of these molecules. Related to this concept, promising
use of GSL synthesis inhibition in animal models of cancer [149-152]
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supports the notion that targeting GSL biosynthesis, for example with
N-butyldeoxynojirimycin (a clinically approved inhibitor for
glucosylceramide synthase), could be further explored in human
cancer as a therapeutic approach, aiming to intervene on GSL
metabolism of tumor cells and modulate GSL shedding, thus lessening
the immunomodulatory effects of GSL.
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